ArticleFrontiers in oncology2026

Immune checkpoint inhibitor-induced inflammatory arthritis as a potential biomarker for long-term response to tislelizumab in advanced head and neck carcinoma: a case report and literature review.

Xiaoqiong Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.